Artificial selection for emamectin benzoate resistance in the biological control agent Orius laevigatus
StatisticsView Usage Statistics
MetadataShow full item record
AuthorBalanza Martínez, Virginia; Villafranca, Estefanía; Mendoza Rivas, José Enrique; Grávalos Riesco, Carolina; Rodríguez Gómez, Amador; [et al.]
Knowledge AreaEdafología y Química Agrícola
SponsorsWe thank the editor and anonymous reviewers for their constructive comments on the manuscript. This research has been supported by the Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (773902-SuperPests). ARG contract is co-financed by Grant PID2020-116897RB-I00 funded by Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación MCIN/AEI/10.13039/501100011033 and the R&D Support Plan of the Polytechnic University of Cartagena.
Realizado en/conUniversidad Politécnica de Cartagena
Bibliographic CitationVirginia Balanza, Estefanía Villafranca, José Enrique Mendoza, Carolina Grávalos, Amador Rodríguez-Gómez, Dina Cifuentes, Pablo Bielza, Artificial selection for emamectin benzoate resistance in the biological control agent Orius laevigatus, Biological Control, Volume 174, 2022, 105024, ISSN 1049-9644, https://doi.org/10.1016/j.biocontrol.2022.105024.
Biological control is occasionally supplemented with insecticides treatments, which may have a significant impact on natural enemies. Typically, selective compounds are chosen to overcome lack of compatibility, but an alternative approach is the use of biocontrol agents resistant to pesticides. Orius laevigatus (Fieber) (Hemiptera: Anthocoridae) is the main predator used to control thrips and other small pests in greenhouses. The avermectin emamectin benzoate is a bioinsecticide developed for the control of lepidopteran pests, reported as moderately to highly toxic to O. laevigatus. Firstly, we studied the variation in susceptibility to emamectin benzoate in 32 wild and commercial populations of O. laevigatus. A 62.4-fold variation in response was found (LC50 from 0.8 mg L−1 to 49.9 mg L−1). The baseline LC50 was 4.8 mg L−1. Secondly, we exploited this intraspecific variation to select four distinct emamectin-resistant strains. After 41–47 selection cycles, four resistant strains were ...
- Artículos 
The following license files are associated with this item: